Mefenamic Acid for Acute Low Back Pain
Mefenamic acid is an appropriate NSAID option for acute low back pain in otherwise healthy adults, but it offers no specific advantage over other NSAIDs and should be used at the lowest effective dose (500 mg initial, then 250 mg every 6 hours) for the shortest duration necessary—typically not exceeding one week.
Evidence-Based Recommendation
The American College of Physicians/American Pain Society guidelines establish that NSAIDs are first-line pharmacologic options for acute low back pain 1. Mefenamic acid, as a nonselective NSAID, falls within this evidence-based recommendation. However, the guidelines do not single out mefenamic acid as superior to other NSAIDs—the evidence shows NSAIDs as a class provide moderate pain relief (10-20 points on a 100-point visual analogue scale) 1.
Specific Dosing Protocol
According to FDA labeling, for acute pain in adults:
- Initial dose: 500 mg
- Maintenance: 250 mg every 6 hours as needed
- Duration: Usually not to exceed one week 2
This time-limited approach aligns with guideline recommendations to use "the lowest effective doses for the shortest periods necessary" 1.
Clinical Context and Comparative Effectiveness
One older comparative trial found mefenamic acid 1500 mg daily performed consistently well against other analgesics for acute low back pain exacerbations, with significantly lower pain scores than paracetamol or dextropropoxyphene combinations 3. However, this evidence is limited and dated. More recent systematic reviews confirm NSAIDs are effective for acute/subacute low back pain but don't demonstrate clear superiority of one NSAID over another 4, 5, 6.
The key point: acetaminophen alone is now known to be ineffective for acute low back pain 4, making NSAIDs like mefenamic acid a more evidence-based choice than previously thought.
Mandatory Risk Assessment Before Prescribing
Before prescribing mefenamic acid, you must assess:
Cardiovascular Risk Factors
- History of myocardial infarction, stroke, or cardiovascular disease
- Hypertension, hyperlipidemia, diabetes
- All NSAIDs (both nonselective and COX-2 selective) are associated with increased MI risk 1
Gastrointestinal Risk Factors
- History of peptic ulcer disease or GI bleeding
- Age >65 years
- Concurrent corticosteroid or anticoagulant use
- Consider co-prescribing a proton-pump inhibitor in higher-risk patients 1
Renal Function
- Pre-existing renal disease is a contraindication
- NSAIDs carry renovascular risks 1
- Mefenamic acid should not be used in significantly impaired renal function 2
Hepatic Function
- Assess baseline liver function
- Mefenamic acid is metabolized by CYP2C9 2
Monitoring Requirements
- No routine laboratory monitoring is required for short-term use (<1 week)
- For any extended use beyond one week (which should be exceptional), reassess pain control and consider alternative therapies 1
- Watch for signs of GI bleeding, cardiovascular events, or renal dysfunction
Critical Pitfalls to Avoid
Do NOT extend treatment beyond one week without reassessment—the evidence supports only short-term benefits 1, 4
Do NOT combine with other NSAIDs—this increases risk without improving efficacy
Do NOT use in patients with contraindications to NSAIDs (active GI bleeding, severe renal impairment, aspirin-sensitive asthma)
Do NOT prescribe without advising patients to stay active—72% of ED physicians incorrectly recommend activity restrictions, which contradicts guidelines 7
Avoid the temptation to order imaging—unless red flags are present, imaging is not indicated and represents low-value care 7
Alternative Considerations
If mefenamic acid is contraindicated or ineffective:
- Other NSAIDs (ibuprofen, naproxen) have equivalent evidence 1, 6
- Skeletal muscle relaxants can be added for short-term relief but cause sedation 1
- Opioids should be reserved for severe, disabling pain uncontrolled by NSAIDs 1
Practical Algorithm
- Confirm no red flags (cauda equina, fracture, infection, malignancy)
- Assess cardiovascular, GI, and renal risk factors
- If low risk: Prescribe mefenamic acid 500 mg initial dose, then 250 mg q6h PRN
- Add PPI if GI risk factors present
- Advise patient to remain active and avoid bed rest
- Limit prescription to 7 days maximum
- If pain persists beyond 4 weeks, reassess and consider non-pharmacologic therapies (spinal manipulation) 1
The evidence is clear: mefenamic acid works for acute low back pain as well as other NSAIDs, but the real clinical skill lies in appropriate patient selection, risk mitigation, and time-limited use 1, 4.